Eli Lilly and Company (NYSE:LLY - Get Free Report)'s share price dropped 1.7% during trading on Monday . The company traded as low as $822.71 and last traded at $825.28. Approximately 1,071,185 shares changed hands during mid-day trading, a decline of 72% from the average daily volume of 3,770,878 shares. The stock had previously closed at $839.96.
Analyst Upgrades and Downgrades
Several brokerages recently issued reports on LLY. Leerink Partners set a $950.00 price target on shares of Eli Lilly and Company in a research report on Friday, January 17th. Guggenheim decreased their price target on shares of Eli Lilly and Company from $973.00 to $928.00 and set a "buy" rating on the stock in a research note on Monday, April 14th. Citigroup dropped their price objective on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a "buy" rating for the company in a research report on Tuesday, January 28th. Berenberg Bank set a $970.00 price objective on Eli Lilly and Company in a research report on Thursday, January 16th. Finally, Cantor Fitzgerald assumed coverage on Eli Lilly and Company in a research note on Tuesday. They set an "overweight" rating and a $975.00 price target on the stock. Two investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $1,017.00.
View Our Latest Research Report on LLY
Eli Lilly and Company Trading Up 1.0 %
The firm has a market capitalization of $792.67 billion, a price-to-earnings ratio of 71.39, a price-to-earnings-growth ratio of 1.40 and a beta of 0.51. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00. The business's fifty day moving average is $827.10 and its 200 day moving average is $818.99.
Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Thursday, February 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. Equities analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.
Insider Transactions at Eli Lilly and Company
In other news, CAO Donald A. Zakrowski sold 1,000 shares of the company's stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the sale, the chief accounting officer now owns 5,840 shares in the company, valued at $4,778,521.60. This represents a 14.62 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 0.13% of the company's stock.
Hedge Funds Weigh In On Eli Lilly and Company
A number of institutional investors have recently added to or reduced their stakes in LLY. CWA Asset Management Group LLC boosted its stake in shares of Eli Lilly and Company by 11.9% during the 4th quarter. CWA Asset Management Group LLC now owns 6,794 shares of the company's stock worth $5,245,000 after acquiring an additional 724 shares during the period. Centerpoint Advisory Group acquired a new position in shares of Eli Lilly and Company in the fourth quarter valued at approximately $514,000. Kentucky Trust Co bought a new position in shares of Eli Lilly and Company during the fourth quarter worth approximately $834,000. Proficio Capital Partners LLC lifted its holdings in Eli Lilly and Company by 30.2% during the 4th quarter. Proficio Capital Partners LLC now owns 6,739 shares of the company's stock worth $5,202,000 after purchasing an additional 1,562 shares during the last quarter. Finally, Cooper Financial Group boosted its stake in Eli Lilly and Company by 35.5% in the 4th quarter. Cooper Financial Group now owns 2,655 shares of the company's stock valued at $2,050,000 after purchasing an additional 695 shares during the period. 82.53% of the stock is currently owned by institutional investors and hedge funds.
About Eli Lilly and Company
(
Get Free Report)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Further Reading
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
